Work

A monoclonal antibody raised against Acinetobacter baumannii capsular carbohydrate exhibits cross-species in vitro binding against Pseudomonas aeruginosa

Year: 2026

Type: article

Abstract: The emergence of extensively drug-resistant bacterial pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa necessitates the innovation of non-small molecule therapies. Monoclonal antibodies represent a promising non-small molecule option. By exploiting shared or similar antigenic structures on these pathogens, it may be possible to develop therapeutic antibodies that target both bacterial species. Here we demonstrate that a previously developed monoclonal antibody targeting A. baumannii (MAb10) has cross-species reactivity to P. aeruginosa in in vitro assays. Despite MAb10's distinct efficacy against A. baumannii, no efficacy was detected against P. aeruginosa in our mouse models of infection. Nevertheless, the unique carbohydrate structures targeted by MAb10 and shared by numerous bacterial species may underscore a possible strategy for developing therapeutic antibodies that can treat infections caused by multiple pathogens.

Source: PLoS ONE

DOI: 10.1371/journal.pone.0340857

Authors: Matthew Slarve, Hadley Jaramillo, Brian Luna, Brad Spellberg

Institution: University of Southern California

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,382